News
3d
Zacks Investment Research on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations sending the company’s stock price spiralling. Despite ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...
Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026. The detailed results from REDEFINE 1 and REDEFINE 2 will be presented at a scientific ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Learn more on NVO stock here.
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...
Late-stage results of Novo Nordisk’s CagriSema suggest the weight loss drug may not be the standout treatment that investors had hoped for. Skip to Main Content. Manage alerts for this article; ...
Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants — less than the ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. See why NVO stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results